Protein misfolding diseases are associated with protein aggregation, oxidative stress and associated inflammatory responses, believed to be critical mediators of cell death. Protein misfolding is involved in more than fifty medical disorders, including several neurodegenerative and skeletal muscle diseases. Novel approaches that selectively attenuate oxidative stress and inflammation in diseased tissue have the potential to provide benefit to millions of patients which currently have few or no beneficial treatment options.
The foundation of ParaMag Biosciences' technology is based upon years of research by Dr. John Voss at the University of California, Davis, focusing on a "spin label" chemistry platform. Dr. Voss' laboratory has engineered a series of proprietary spin labeled naturally occurring antioxidants that selectively bind to amyloid and provide neuronal protection from toxic effects of amyloid-beta. These molecules have been termed paramagnetic amyloid ligands (PALs) as they are not only neuroprotective but also able to be visualized in the brain with Magnetic Resonance Imaging.
Therapy: The core competency of this UC Davis spin-out company lies in the design and development of novel, paramagnetic catalytic antioxidants that can enter cells and prevent the toxic event of protein misfolding.
Diagnostics: Our theranostic paradigm using PALs unites diagnostic and therapeutic applications allowing for a single agent to diagnose, monitor, and treat the disease. These theranostic agents provide a transition from conventional medicine to a contemporary personalized and precise approach.
Dr. Voss , Founder and President, is a professor in the Department of Biochemistry and Molecular Medicine in the Medical School at UC Davis and Chair of the UC Davis Graduate Program of Biophysics. He is a renowned expert in using biophysical methods to study the structural basis for Alzheimer’s Disease. In addition, Dr. Voss has over 20 years of experience using EPR spectroscopy to study the of biochemistry radicals and spin labels. His research at the University of California, Davis has been related to the study of protein biophysics and to oxidative stress and the modulation of pathogenic protein and peptide conformations. He is the inventor of the platform for our small molecules that bind intra-cellular Alzheimer’s pathology.
Dr. Rogers, Founder and Chief Development Officer, is a Board Certified Toxicologist and entrepreneur with extensive experience in preclinical drug development. He has been involved many start-up biotechnology companies and has experience in the design and implementation of numerous preclinical development plans that have culminated in well over 100 INDs and over 20 NDAs, several indicated for neurological disease. He is also co-founder and CEO of Pacific BioDevelopment, LLC, his own preclinical consulting firm, serving the biotechnology community for over 20 years.
Dr. Reynoso, Founder and Chief Operating Officer, is an entrepreneur and trained immunologist with 10 years of drug development experience at Genentech, Syntex and Arris Pharmaceuticals. She has been involved in several startups and has significant experience in operations and business development. She is very familiar with the drug development process and has worked with contract research organizations extensively.
Specialist in Preclinical & Pharmacokinetics
Jerry is an expert in the areas of Pharmacology and Pharmacokinetics. He has over 30 years of experience, including Genentech, Celtrix Pharmaceuticals, UC Berkeley, and Stanford University. He has written ADME sections for dozens of INDs, clinical pharmacology, and NDAs. His experience is essential to develop and evaluate non-clinical and clinical pharmacokinetics and pharmacology programs for drug development and regulatory submissions.
Specialist in Regulatory Affairs & Orphan Disease
Ira is the senior regulatory affairs officer and Vice President at Pacific Bio Development, LLC with over 20 years of experience. Ira’s expertise comes from his experience at Genentech and at Pacific BioDevelopment where he has been involved with over 100 INDs and NDAs. He has particular expertise in orphan drug filings.
Specialist in Medicinal Chemistry
Andy is a medicinal chemist and expert in preclinical and small molecule pharmaceutical development. He has been involved in all aspects of drug discovery and development in multinational pharmaceutical and biotechnology companies in the U.S. and U.K.. Dr. Pennell has over 25 years of experience in the pharmaceutical industry, with a focus on discovering and developing new therapeutics leading discovery and development teams in a variety of therapeutic areas including autoimmune, inflammatory, oncologic, bacterial, viral, cardiovascular, metabolic and CNS diseases.
Specialist in Neuroscience & Clinical Development
Jonas has more than 20 years of experience in the field of neuroscience at both academic and biopharmaceutical organizations spanning multiple disease areas, including Parkinson’s, Alzheimer’s, and ALS. He has over 20 years of experience in translational and early clinical development. He has previously served as Chief Medical Officer at Tranquis Therapeutics, SVP of Clinical Development at Alkahest, Medical Director at Denali Therapeutics, and Director of Neuroscience Discovery Medicine at UCB Pharma. Before his move into the biopharmaceutical field, he led the Clinical Neuroscience Research Unit at Yale School of Medicine.
Specialist in Entrepreneurship
Zane has 15 years of experience in science-based entrepreneurship in the biotechnology, pharmaceutical and clean energy industries. He has worked for venture capital and investment firms focused on the life sciences, where he evaluated investment opportunities, helped raise new venture funds and advised companies on financing, business development, intellectual property licensing, M&A and clinical trial design. Zane obtained his Ph.D. in chemistry from UC Davis with a designated emphasis in biotechnology and translational research, B.S. in physics, and was a UC Davis Howard Hughes Medical Institute Scholar.
Specialist in Development and Commercialization
Dr. Ruegg is a drug development executive with over 25 years of biopharmaceutical experience. He has extensive experience advancing novel therapies. Dr. Ruegg received his Ph.D. degree from Johns Hopkins University School of Medicine and was a Cancer Research Institute Fellow at Stanford University School of Medicine. He has led companies spanning from start-up to commercial-stage companies across multiple therapeutic areas for both biologic and small molecule drugs. Dr. Ruegg has held leadership positions at Revance, CoTherix, Intermune, AP Cells, Dendreon, Amphivena and Parvus Therapeutics.